Three main subtypes have been described, namely, luminal estrogen receptor (ER)-positive, HER2-enriched and triple negative breast carcinomas (TNBCs) that do not express ER, PR and HER2 [89]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.